– Collaboration represents the first time the ACC’s PINNACLE Registry Research Alliance will be used for clinical trial recruitment – Paris, France and Tarrytown, New York – December 19, 2013 – Sanofi (EURONEXT : SAN and NYSE : SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ : REGN) announced today an innovative collaboration with the American College […]
Global agreement strengthens AstraZeneca’s commitment to diabetes, a key growth platform in a core strategic area for the company December 19 , 2013 – AstraZeneca today announced an agreement under which AstraZeneca will acquire the entirety of Bristol-Myers Squibb’s interests in the companies’ diabetes alliance for an initial consideration of $2.7 billion on completion and up […]
New resources housed on T1EverydayMagic.com combine the expertise of Lilly Diabetes with the magic of Disney INDIANAPOLIS, Dec. 19, 2013 /PRNewswire/ — Lilly Diabetes and Disney today announced that their custom books for children and families with type 1 diabetes are now available online. The digital books explore real-life challenges and stories of children with […]
MALVERN, Pa. and MONTREAL, Dec. 19, 2013 /PRNewswire/ — Endo Health Solutions (NASDAQ: ENDP) (“Endo”) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (“HSR Act”) in connection with Endo’s proposed acquisition of Paladin Labs Inc. (TSX: PLB) (“Paladin Labs”) was terminated by the United States Federal Trade […]
NEW YORK– December 19, 2013 — (BUSINESS WIRE)–Forest Laboratories, Inc. (NYSE:FRX) announced today that FETZIMA™ (levomilnacipran ER capsules), is now available in pharmacies throughout the United States. FETZIMA was approved by the U.S. Food and Drug Administration (FDA) for the treatment of Major Depressive Disorder (MDD), also known as depression, in adults in July 2013. […]
Agreement secures full Elekta solution across the McLaren enterprise STOCKHOLM, December 18, 2013 – The ability to effectively manage data across disparate health systems to help drive quality care will be a cornerstone for health systems of the future. Elekta is proud to announce today that it has joined forces with Michigan-based McLaren Health Care […]
— High Cure Rates Observed with Single Tablet Regimen May Eliminate Interferon and Ribavirin from HCV Therapy for Genotype 1 Patients — — U.S. NDA Submission Planned for Q1 2014– FOSTER CITY, Calif.–(BUSINESS WIRE)–Dec. 18, 2013– Gilead Sciences, Inc. (Nasdaq: GILD) today announced topline results from three Phase 3 clinical trials (ION-1, ION-2 and ION-3) evaluating the […]
TARRYTOWN, N.Y., Dec. 18, 2013 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for standard review the Company’s supplemental Biologics License Application (sBLA) for EYLEA® (aflibercept) Injection for the treatment of Diabetic Macular Edema (DME). Under the Prescription Drug User Fee Act (PDUFA), the goal for a standard review of an sBLA […]
Menlo Park, California and INGELHEIM, Germany, 18 December, 2013 – Boehringer Ingelheim and Circuit Therapeutics have entered into a research collaboration agreement for the discovery of new ways of treating psychiatric disorders. Circuit Therapeutics provides an innovative platform that allows the identification and characterization of drug targets from brain circuits involved in normal and pathological behaviors. […]
PITTSBURGH, Dec. 18, 2013 /PRNewswire/ — Mylan Inc. (Nasdaq: MYL) today announced that it has received all regulatory approvals and has completed an agreement with Pfizer for the exclusive worldwide rights to develop, manufacture and commercialize a novel long-acting muscarinic antagonist (LAMA) compound for various indications. Mylan expects that this product, which is ready to […]